Company

Product

Description

Indication

Status

Date

Phase II

Bionomics Ltd., of Adelaide, Australia

BNC-210

Alpha-7 nicotinic acetylcholine receptor

Post-traumatic stress disorder

Trial did not meet primary endpoint of decrease in PTSD symptoms as measured by CAPS-5 at 12 weeks

10/2/18

Cocrystal Pharma Inc., of Atlanta

CC-31244

Non-nucleoside inhibitor

Hepatitis C

Agreement for investigator-initiated study with the Humanity & Health Research Centre in Hong Kong

10/8/18

Phase III

Eisai Co. Ltd., of Tokyo

Belviq (lorcaserin)

Activates serotonin 2C receptors

Prevention and remission of type 2 diabetes mellitus

Data from the phase IIIb/IV CAMELLIA-TIMI61 cardiovascular outcomes study, published in The Lancet, showed treatment vs. placebo reduced incident of T2DM in pre-diabetes patients by 19% (p=0.038); in patients with TDM2 at baseline, treatment increased rate of remission of hyperglycemia vs. placebo (p=0.049) and reduced hemoglobin A1C; patients with baseline HBA1c greater than 8% had a net reduction of 0.5% at 1 year on Belviq; treatment also reduced risk of a composite of microvascular events of incident microalbuminuria, diabetic retinopathy or diabetic neuropathy by 21% in patients with T2DM (p=0.001)

10/5/18


Notes

The date indicated refers to the BioWorld Clinical data table in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.

No Comments